7th Jul 2005 07:00
Sinclair Pharma PLC07 July 2005 SINCLAIR PHARMA PLC Sinclair Pharma Licenses Xclair(TM) in Brazil and Portugal Godalming UK, 7 July, 2005: Sinclair Pharma plc ("Sinclair" or the "Company")(SPH.L), the specialty pharmaceutical company, announces two new sales andmarketing agreements for Xclair(TM), its product for the treatment of radiationdermatitis. Radiation dermatitis is a common side effect of radiotherapy for thetreatment of cancer. Under the terms of the Xclair(TM) agreements, the product has been exclusivelylicensed to Pharmis Group for sale in Portugal and in Brazil. Pharmis Groupfocuses on the marketing and sales of pharmaceutical products exclusively to thehospital market place. Pharmis plans to market Xclair(TM) through its focused,specialty oncology sales representatives through the major treatment centres inPortugal and Brazil. The marketing strategy will aim to increase awareness ofthe benefits of Xclair(TM) in treating the debilitating effects on the skin ofradiation dermatitis. These 10 year agreements include license fees and minimumsales commitments. Dr Michael Flynn, CEO of Sinclair, said: "We now have marketing and salesagreements in place for Xclair(TM) in eight territories including the US. Inthe absence of any clear established brand for the treatment of radiationdermatitis we believe that Xclair(TM) will be welcomed as an effective topicalproduct in cases where radiation therapy causes inflammation and discomfort ofthe skin and we hope to create a global brand." Antonio Barbosa , Chairman and Chief Executive Officer of Pharmis, added: "We are delighted that Sinclair recognizes Pharmis as its partner of choice inbringing this exciting product to market in our home market of Portugal as wellas in one of the major developing pharmaceutical markets in South America. "Xclair(TM) will expand our presence in the hospital-based setting, consistentwith our strategy of growing our franchise in oncology and complementarytherapies. There is a significant unmet need for an effective treatment forthis condition and we are excited about the prospect of marketing Xclair(TM)which represents a major advance in the treatment of radiation dermatitis." END Enquiries: Sinclair Pharma plc Dr Michael Flynn, CEO Tel: 01483 426 6444 John Barrington-Carver (Corporate PR) Tel: 07831 655 630 Financial Dynamics Ben Atwell or Lucy Briggs Tel: 0207 831 3113 Notes to editors: Sinclair Pharma plc Sinclair Pharma plc based in Godalming in the UK, is quoted on the AlternativeInvestment Market (AIM) on the London Stock Exchange and has focused on theacquisition and development of niche patented pharmaceutical products in thefields of oral health, oncology support and dermatology, and bringing them tothe international market place via out-licensing partners. The Company combinesproduct evaluation, product development, regulatory and business developmentexpertise to add value to its acquired and in-house developed products. A keyelement of the Sinclair business model is to minimise risk and exposure byavoiding involvement in lengthy R&D programmes and rapidly achieving globaldistribution through a network of marketing partners. The Company has alreadylicensed its products for distribution in over 40 countries around the world. www.sinclairpharma.com Pharmis Pharmis is a specialty marketing and distribution company based in Portugal withsubsidiaries in Brazil and Spain. The company, established in 1991 focuses onhospital products in oncology, pulmonology and critical care medicine. Pharmishas agreements with partners of assured quality such as Skyepharma, Doblar,CellPep, Nexpharma and Sterilyo-GSK. Brazil represents the 9th largest pharmaceutical market and accounts for 40% ofthe Latin American market. "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of1995: Some or all of the statements in this document that relate to futureplans, expectations, events, performances and the like are forward-lookingstatements, as defined in the US Private Securities Litigation Reform Act of1995. Actual results of events could differ materially from those described inthe forward- looking statements due to a variety of factors. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Sinclair Pharma